On May 10, 36 Kr, a well-known Chinese venture capital platform, released the 2023 "36 Under 36" list of entrepreneurs and investors, which has garnered extensive trust and attention within the venture capital community.

Dr. Dudu Tong, the R&D Director of Leman Biotech, has been actively participating in discussions and conferences related to the application of artificial intelligence (AI) in the biotech industry. As AI continues to generate significant interest and expectations, Leman Biotech's AI pipeline has achieved remarkable milestones, gaining attention in the field.

Leman Biotech, in collaboration with XtalPi Technology, has reached a significant milestone in the AI Enabled Superkine pipeline. Using the MetaAI-10 computational model and yeast demonstration technology, Leman Biotech successfully conducted high-throughput screening of superkine mutants, resulting in over 5000 immunometabolic regulators with exceptionally high affinity. Patent application (number: 2022116277856) has been filed for the invention.

Leman Biotech received the prestigious "CGT Industry Star" Technology Breakthrough of the Year award at the CGT Asia 2023 3rd Asia Cell and Gene Therapy Innovation Summit held in Shanghai on April 3-4, 2023. Dr. Dudu Tong, R&D Director of Leman Biotech, received the award on behalf of the company.

Leman Biotech, represented by its co-founder Dr. Yugang Guo, R&D director Dr. Youjia Li, and Dr. Dudu Tong, recently visited Xiangxue Life Sciences, Ltd. The delegation was warmly welcomed by Mr. Lun Zeng, CEO, Dr. Haiping Gong, Vice President, Dr. Yingjie Huang, Chief Medical Officer, Dr. Shi Zhong, Chief Scientist, Dr. Hongjun Zheng, Deputy Director of R&D, and other R&D scientists from Xiangxue Life Sciences. The purpose of the visit was to foster exchange and collaboration between the two companies.

Leman Biotech has recently received extensive evaluations from renowned institutions and companies in the Guangdong, Hong Kong, Macao, and Greater Bay Area. Notable entities such as Guangdong Hengjian Investment Holdings Limited, Hong Kong Cyberport, top PE BPEA EQT, Zhuhai Zhengling Venture Capital, Zhuhai Zhengfang Group, and Xiangxue Pharmaceutical have assessed Leman Biotech's core technology, R&D progress, talent team, and development plans.

On March 8, 2023, Leman Biotech was invited to participate in the EPFL Engineering Industry Day at the Swiss Federal Institute of Technology in Lausanne (EPFL). This event, which was interrupted for three years due to the Covid-19 epidemic, is finally back at the Swiss Science and Technology Conference Center this year. The event aims to showcase the research and innovation capabilities of the EPFL School of Engineering, its collaboration with the industry, and the transfer of research technology, as well as its social impact.

In a recent report by Labiotech.eu, the renowned online media focusing on the European biotechnology industry, Leman Biologics has been recognized as one of the 13 exceptional biotech companies in Switzerland's "Health Valley." The report highlights Leman Biologics' groundbreaking work in developing the metabolic regulator protein IL-10-Fc, which enhances the effectiveness of existing immunotherapy treatments like CAR-T by boosting T-cell metabolism.